Reply to J.J. Tosoian et al


Published in:
Journal of Clinical Oncology

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
© 2016 by American Society of Clinical Oncology. This work is made available online in accordance with the publisher’s policies. Please refer to any applicable terms of use of the publisher.

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen’s institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person’s rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

Open Access
This research has been made openly available by Queen’s academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback

Download date:19. Jul. 2024
Reply to J.J. Tosoian et al

Potential overtreatment of prostate cancer has increased the use of active surveillance (AS). We agree with Tosoian and Carter that variable inclusion criteria used in previous studies and the lack of mature randomized data mean that there is uncertainty in identifying the ideal patient population to receive AS. We would like to confirm that the endorsed Cancer Care Ontario (CCO) guideline applied a quality assessment of the included studies, and this was taken into consideration during our evaluation. The original CCO guideline did not include any strength-of-recommendation ratings, and none were added according to ASCO endorsement methodology.

For low-risk cancer, there is a lack of compelling evidence showing that immediate treatment improves overall survival. The SPCG-4 (Scandinavian Prostate Cancer Group Trial Number 4) trial randomly assigned patients to watchful waiting versus radical prostatectomy and found a nonsignificant 3.8% mortality reduction for low-risk patients in the prostatectomy group with a median follow-up of > 13 years. However, it is not clear whether this difference applies to screening-detected patients, and whether AS differs from watchful waiting. A more contemporary randomized trial showed no survival benefit from radical prostatectomy versus observation in low-risk patients through at least 12 years of follow-up.

We agree that more research is needed to identify the ideal patient group for AS. The ASCO endorsement acknowledges that variable inclusion criteria and that treatment decisions should be made in consideration of the individual patient. To date, there are no data suggesting that any patient characteristics (including patients classified as very-low risk by the National Comprehensive Cancer Network) indicate a need for immediate treatment of low-risk patients. Indeed, recent evidence suggests rates of upgrading and upstaging were comparable in black and white men with low-risk prostate cancer. Two of the largest, most mature AS studies had the broadest inclusion criteria and both included patients with intermediate-risk disease. To date, these studies have demonstrated low rates of metastases and cancer-related mortality with 50% to 63.5% of patients remaining untreated at 10 years. Many of these patients were recruited before the introduction of the International Society of Urological Pathology modified Gleason grading system in 2005, with studies suggesting that up to one third of Gleason 3+3 tumors would now be classified as Gleason 3+4. Furthermore, biopsies now increasingly include greater numbers of cores coupled with multiparametric staging using magnetic resonance imaging scans, which has led to grade and stage migration, suggesting that these results reflect worst-case scenarios. If it is demonstrated that very-low-risk versus low-risk patients have different long-term survival outcomes after AS, this can inform future clinical practice and guidelines, but until data become available, we feel that the ASCO endorsement with the described acknowledgment of patient heterogeneity best summarizes currently available evidence.

**Ronald C. Chen**

University of North Carolina, Chapel Hill, NC

**R. Bryan Rumble**

American Society of Clinical Oncology, Alexandria, VA

**Suneil Jain**

Queen’s University Belfast, Belfast, United Kingdom

**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Disclosures provided by the authors are available with this article at www.jco.org.

**REFERENCES**


DOI: 10.1200/JCO.2016.70.2084; published online ahead of print at www.jco.org on October 3, 2016.
**AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST**

Reply to J.J. Tosoian et al

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

<table>
<thead>
<tr>
<th>Author</th>
<th>Consulting or Advisory Role</th>
<th>Research Funding</th>
<th>Employment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ronald C. Chen</td>
<td>Medivation/Astellas Pharma</td>
<td>Accuray</td>
<td>Park Lane Terrace (I)</td>
</tr>
<tr>
<td>Suneil Jain</td>
<td>Janssen-Cilag, Ferring Pharmaceuticals</td>
<td>Janssen-Cilag, Ferring Pharmaceuticals</td>
<td>Janssen-Cilag, Astellas Pharma, Ferring Pharmaceuticals</td>
</tr>
</tbody>
</table>